Jag Capital Management LLC Buys 14,159 Shares of Natera, Inc. (NASDAQ:NTRA)

Jag Capital Management LLC raised its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 175,590 shares of the medical research company's stock after buying an additional 14,159 shares during the period. Natera comprises 2.7% of Jag Capital Management LLC's portfolio, making the stock its 14th biggest position. Jag Capital Management LLC owned about 0.14% of Natera worth $22,291,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera during the second quarter worth approximately $28,000. Quarry LP increased its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after buying an additional 190 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock worth $35,000 after buying an additional 108 shares in the last quarter. Covestor Ltd increased its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after buying an additional 95 shares in the last quarter. Finally, Tobam acquired a new stake in shares of Natera during the second quarter worth approximately $74,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on NTRA. UBS Group dropped their price objective on shares of Natera from $160.00 to $145.00 and set a "buy" rating for the company in a report on Friday, August 9th. Stephens reissued an "overweight" rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. The Goldman Sachs Group raised their price target on shares of Natera from $125.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. Leerink Partners raised their price target on shares of Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Finally, Sanford C. Bernstein raised their price target on shares of Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $125.69.

Natera Stock Down 0.1 %

NASDAQ NTRA traded down $0.14 on Monday, reaching $133.97. The company had a trading volume of 1,830,201 shares, compared to its average volume of 1,308,291. The firm has a market capitalization of $16.57 billion, a price-to-earnings ratio of -54.74 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a 1-year low of $46.96 and a 1-year high of $140.00. The company's fifty day moving average is $124.35 and its 200-day moving average is $113.91.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same period in the prior year, the business earned ($0.97) EPS. The company's revenue for the quarter was up 58.1% compared to the same quarter last year. On average, research analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jonathan Sheena sold 12,000 shares of the company's stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the sale, the insider now directly owns 287,441 shares of the company's stock, valued at approximately $34,783,235.41. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Steven Leonard Chapman sold 5,583 shares of the company's stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $118.91, for a total value of $663,874.53. Following the sale, the chief executive officer now directly owns 200,710 shares of the company's stock, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the transaction, the insider now directly owns 287,441 shares in the company, valued at approximately $34,783,235.41. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,464 shares of company stock valued at $5,849,977. 7.60% of the stock is owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.